The Pancreatic Cancer Immune Tumor Microenvironment Is Negatively Remodeled by Gemcitabine While TGF-β Receptor plus Dual Checkpoint Inhibition Maintains Antitumor Immune Cells
Scientists hypothesized that TGF-β receptor inhibition may alter Pancreatic ductal adenocarcinoma progression and antitumor immunity in the tumor microenvironment.